Skip to main content
  • Abbott got CDSCO panel nod to market Lidocaine and Diltiazem combination

    Abbott received permission from the Subject Expert Committee to market a fixed dose combination (FDC) of Lidocaine and Diltiazem, after detailed deliberation by committee.

    Abbott has presented a Phase III clinical trial report before the committee and after detailed deliberation, the committee recommended grant of permission for manufacturing and marketing of the proposed FDC.

  • Opportunity for M.Pharm as Bench Chemist (5 posts) at CDSCO - Government Jobs

    The Central Drugs Standard Control Organization (CDSCO) is the Central Drug Authority for discharging functions assigned to the Central Government under the Drugs and Cosmetics Act. CDSCO has six zonal offices, four sub-zonal offices, 13 port offices and seven laboratories under its control.

    Post : Bench Chemist

  • Wockhardt gets CDSCO approval to export Sputnik Vaccines

    Wockhardt Limited has received permission from the Central Drugs Standard Control Organization (CDSCO) to export up to 80 million doses of Sputnik Light and up to 20 million doses of Sputnik V Component I vaccine.

    Wockhardts Bulk vaccine and Fill-Finish manufacturing facilities at Waluj and Shendra, Aurangabad respectively were jointly inspected and approved by Drug inspectors from CDSCO (West zone) & Aurangabad State FDA and Expert from CDL Kasauli to receive export NOC.

  • Career for M.Pharm, M.Sc at CDSCO - Central Government | Pay upto Rs. 92,300 pm

    The Central Drugs Standard Control Organization (CDSCO) is the Central Drug Authority for discharging functions assigned to the Central Government under the Drugs and Cosmetics Act. CDSCO has six zonal offices, four sub-zonal offices, 13 port offices and seven laboratories under its control.

    Post : Junior Scientific Assistant

  • Opening for BPharm, MPharm, PharmD (14 posts) at CDSCO - Central Government

    The Central Drugs Standard Control Organization (CDSCO) is the Central Drug Authority for discharging functions assigned to the Central Government under the Drugs and Cosmetics Act. CDSCO has six zonal offices, four sub-zonal offices, 13 port offices and seven laboratories under its control.

    Post: Research Scientist, Technical Data Associates

  • CDSCO approves Covovax, Corbevax and Molnupiravir to fight COVID-19

    Union Health Minister Dr Mansukh Mandaviya on Tuesday, 28 December, announced that the Central Drugs Standard Control Organisation (CDSCO) had approved two more COVID-19 vaccines and COVID-19 pill for restricted emergency use in India.

    Two COVID-19 vaccines which are approved for restricted emergency use in India named Corbevax and Covovax. And Covid-19 pill from merck Molnupiravir is amongst the approved antiviral for COVID-19 in India.

  • Strides Pharma gets CDSCO nod to export 50 mn doses of Sputnik vaccine

    Strides Pharma gets No Objection Certificate (NOC) from Central Drugs Standard Control Organization (CDSCO) to export 50 million doses of Russia based, Sputnik vaccine which is developed by RDIF. The Russian COVID-19 vaccine Sputnik V (Gam-COVID-Vac) is an adenoviral-based, two-part vaccine against the SARS-CoV-2 coronavirus. Initially produced in Russia, Sputnik V uses a weakened virus to deliver small parts of a pathogen and stimulate an immune response.

  • GSK gets CDSCO panel nod for inactivated influenza vaccine

    GSK India has received a positive recommendation from the Subject Expert Committee, SEC, of CDSCO for inactivated influenza vaccine, split virion vaccine. The SEC recommended that permission may be granted for ages more than 64 years.

    Inactivated influenza, split virion vaccine sold under brand name Fluarix Tetra in India which helps to protect from influenza (flu). It works by exposure to a small dose of the flu virus which helps the body to develop immunity against the disease. It will not treat an existing flu virus infection.

  • NATCO receives Emergency Use approval for Baricitinib tablets for Covid-19 treatment

    Natco Pharma Limited has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India. Baricitinib in combination with Remdesivir, is used for treatment of COVID-19 positive patients.

  • Recruitment for Pharmacy Degree as Junior Scientific Assistant at CDSCO - Government Jobs

    The Central Drugs Standard Control Organisation(CDSCO) under Directorate General of Health Services,Ministry of Health & Family Welfare,Government of India is the National Regulatory Authority (NRA) of India.

Subscribe to CDSCO

Search this website